In the fall of 2009, a group of New Zealand scientists were putting the finishing touches on a new therapeutic to help cancer patients recover from chemotherapy, in preparation for a clinical trial. All they had left to do was choose a flavor.
“It was no easy task,” says Arie Geursen, general manager of LactoPharma, the entity developing the therapeutic, presented in the form of an ice cream. “Everyone has their favorites. We were already leaning toward strawberry since one of the bioactive agents was tinting the ice cream pink… But the decision really came down to who won the taste tests. Strawberry came out on top.”
Development of the ice cream, named ReCharge, began 8 years ago with the formation of LactoPharma, a collaborative research venture between the University of Auckland, the New Zealand government, and the country’s largest dairy company, Fonterra Ltd.
When Cancer ...
